AstraZeneca Plc (AZN)

53.87
1.10 2.10
NYSE : Health Technology
Prev Close 55.00
Open 54.59
Day Low/High 53.76 / 55.27
52 Wk Low/High 36.15 / 57.44
Volume 4.46M
Avg Volume 5.23M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 140.76B
EPS 0.50
P/E Ratio 24.54
Div & Yield 1.37 (2.48%)
Lunacy on Interest Rates

Lunacy on Interest Rates

Across all sectors, stocks are rising in tandem with rates -- but I think this stupidity will end soon.

AstraZeneca Zigs and Zags

The shares have more moves than a shortstop batting .110. From bottom to high to bottom to high, AstraZeneca (AZN) has traversed about 9 points today. More moves than a shortstop batting .110.

The Early Bird Gets the Worm, Part Deux

I sold out of my AstraZenca long for a nice gain. I just sold out of the balance of my AstraZeneca (AZN) long rental at $72.30, a nice way to start the day.

The Early Bird Gets the Worm

Just collected some profits on my premarket AstraZeneca purchase. I just sold out more than half of my AstraZeneca (AZN) long rental at $71.90, for more than a $1.20-per-share gain.

Morning Market Look

Maybe the rally has simply been too soon and too fast. There was little in the way of weekend news that would lead one to expect a down futures opening. So, maybe the rally has simply been too soon and too fast. There was some dovish news on Bernank...

Pfizer, AstraZeneca CEOs Set to Appear Before UK Lawmakers

Pfizer, AstraZeneca CEOs Set to Appear Before UK Lawmakers

In an effort to smooth approval for its $106 billion merger, Pfizer and AstraZeneca are set to meet UK regulators on Tuesday who are wary a deal will lead to British job cuts.

Worry About Bonds, Not Bubbles

Worry About Bonds, Not Bubbles

The biggest overvaluation is the undervaluation of risk in that market.

An Economy Stuck in First Gear

An Economy Stuck in First Gear

These two structural issues go a long way toward explaining this sluggish growth.

AstraZeneca Spurns Pfizer Bid, Earnings News & a Jim Cramer Pick

AstraZeneca Spurns Pfizer Bid, Earnings News & a Jim Cramer Pick

LinkedIn is among loss leaders on the tech scene in 2014, and its earnings report Thursday did little to improve investors' outlook.

Pfizer's Blockbuster Bid, Yahoo's Laugh Track & Americans Take Off

Pfizer's Blockbuster Bid, Yahoo's Laugh Track & Americans Take Off

Pharma giant Pfizer revealed Monday it made a $99 billion bid for AstraZeneca in January and had contacted its rival again on April 26 about a takeover.

The Revenge of the Nerds

The Revenge of the Nerds

Suddenly these companies have gone from embarrassing to, yes, embarrassingly rich.

Covered AstraZeneca Short

That was quick. I have covered my AstraZeneca (AZN) short for a quick profit.

Adding to AZN Short

I am adding to my AstraZeneca (AZN) short at $67.35 now.

Day Ahead: Earnings in Full Swing

Day Ahead: Earnings in Full Swing

Futures point higher; AstraZeneca rises on bid talk.

Shorting AZN

I doubt this story. A London Sunday Times article suggests that Pfizer (PFE) considered acquiring AstraZeneca (AZN), but the talks stalled and will not resume. I am doubtful of this story and I have shorted AZN, +$6 in premarket trading as the compa...

Array CEO: Partnerships Smart While Cancer Drug Develops

Array CEO: Partnerships Smart While Cancer Drug Develops

Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.

Analyst Says Actavis' $25 Billion Purchase of Forest Labs is Smart

Analyst Says Actavis' $25 Billion Purchase of Forest Labs is Smart

James Molloy, Managing Director at Janney Montgomery Scott explains why Actavis buying Forest Labs is a smart for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.

European Stocks Rally on Fed Guidance; Drugmakers Strike Deals

European Stocks Rally on Fed Guidance; Drugmakers Strike Deals

The U.K.'s AstraZeneca and Germany's Bayer spend up to a combined $7.2 billion shoring up their portfolios. Laura Board reports from London.

Keep Calm and Carry EWU

Keep Calm and Carry EWU

The UK is the next geographic hotspot. Play it with this ETF.

S&P Lifts U.S. Credit Outlook

S&P Lifts U.S. Credit Outlook

Credit rating agency Standard & Poor's upgrades its credit outlook for the U.S. government to Stable from Negative.

Stocks Follow Japan's Lead Upward

Stocks Follow Japan's Lead Upward

Merger Monday begins with AstraZeneca buying Pearl, while Apple could announce iRadio and Google may purchase Waze as futures look up.

Millions for Fish Oil

Millions for Fish Oil

Stocks are up as AstraZeneca pays millions for Omthera, while Valeant buys Bausch & Lomb and Tiffany's earnings shine.

The Biotech Revaluation Is On

The Biotech Revaluation Is On

These four names in particular have made some stunning moves.

AstraZeneca estimates cut at Leerink

Trending Now: HPQ Announces 10% Increase in Quarterly Dividend

Trending Now: HPQ Announces 10% Increase in Quarterly Dividend

Hewlett-Packard announces a 10% increase in its quarterly dividend. Brittany Umar has details on that as well as a look at the day's other most searched trends on the Web.

IPOs: LifeLock, Luxfer, Regulus

IPOs: LifeLock, Luxfer, Regulus

LifeLock looks to be the best offering for the IPOs planned on Wednesday according to IPO Desltop President Francis Gaskins.

Three U.K. Gold Medalists

Three U.K. Gold Medalists

These companies are performing like champions, despite a weak British economy.

Trading Abbott for Bristol Myers

Trading Abbott for Bristol Myers

Stephanie Link, director of research at TheStreet, eliminated her position in Abbott to build a position in Bristol Meyers.

Apple Pays Proview $60 Million in iPad Dispute: Hot Trends

Apple Pays Proview $60 Million in iPad Dispute: Hot Trends

A look at some of the day's most searched topics on the Web, includingApple as the company shells out $60 million to settle its iPad namingdispute with Proview Technology.

The Next Big Thing in Biotech: M&A

The Next Big Thing in Biotech: M&A

Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.